
By Dr. Zahid Khan, a consultant gynaecologist working in the UAE and CEO of femtech firm, My ANNA Health.
Endometriosis affects an estimated one in 10 women of reproductive age globally—approximately 190 million women. Yet, despite its prevalence, research into this condition has been grossly underfunded and underprioritised.
Recent statistics suggest that only 2 percent of medical research funding is spent on pregnancy, childbirth, and female reproductive health. This is despite one in three women reporting a reproductive or gynaecological health problem.
It is under-researched and underfunded compared to other chronic conditions, contributing to poor diagnostic tools and treatment options. For example, in the U.S., the National Institutes of Health (NIH), the world’s largest source of biomedical research funding, allocated US$41.7bn in 2022.
Despite this, only US$16m – or 0.038 per cent of the NIH budget – was designated for endometriosis research.
Given that endometriosis affects around 11 per cent of US women over their lifetime, this equates to just US$2 per patient per year. In stark contrast, diabetes, which impacts 12 per cent of US women, receives over 1,500 per cent more funding per woman, with an estimated US$31.30 allocated per female patient.
This disparity in funding not only limits our understanding of the disease but also delays the development of effective treatments and diagnostic tools.
An encouraging advancement in the battle against endometriosis is the creation of new AI tools like ANNA (Artificial Narrow Neural Assistant). Designed to aid early diagnosis and reduce the long wait times associated with specialist consultations, ANNA is an AI-driven platform that is being trialled in primary care settings in the UK.
Unlike traditional diagnostic methods that rely on invasive procedures like laparoscopy, ANNA uses a sophisticated algorithm to analyze symptoms and suggest the likelihood of endometriosis. ANNA has been tested with over 160 patients, showing a 100 percent agreement with specialist diagnoses, a clear indicator of its potential in revolutionizing early diagnosis.
ANNA is multilingual and designed with a culturally sensitive avatar, breaking down language barriers and providing healthcare access to women from diverse backgrounds. It can be used independently by patients or in consultation with healthcare professionals, guiding them on when to seek specialist help and offering pain management strategies. By integrating ANNA into primary care, the timeline for diagnosis can be significantly shortened, allowing women to receive timely treatment and improve their quality of life.
Research into and adoption of non-invasive diagnostic tools, like ANNA, is critical to reducing the years of suffering that many women endure. Beyond diagnosis, we need to focus on better treatment options that go beyond hormonal therapies and surgery.
These treatments often have severe side effects, and in many cases, they aren’t curative. Research into the causes of endometriosis—whether genetic, hormonal-, or immunological—will pave the way for more targeted therapies that address the disease at its source.
The importance of awareness cannot be overstated. Primary care providers need to be better trained to recognise the symptoms of endometriosis early on. Public health campaigns should inform women about what constitutes normal menstruation and when they should seek help. Too many women suffer in silence, told by doctors that their pain is “normal” or dismissed with misdiagnoses.
Abu Dhabi is investing in making real changes, developing these cutting-edge surgical techniques for endometriosis and setting up efficient specialized care centers. At our Centre of Excellence, we perform six to seven endometriosis surgeries a week, with recurrence rates below 9 percent.
These are promising advancements, but the next challenge is scaling up these technologies and advancements, ensuring that they are accessible to women worldwide.
Newsletter
Sign up for free weekly updates
The latest femtech news, research and investment, straight to your inbox.









